U.S. Markets close in 2 hrs 5 mins

Spanish Peaks Confirms Puration Million Dollar Cannabis Infused Beverage Collaboration Agreement and Issues Update On Beverage Production

DALLAS, TX / ACCESSWIRE / December 29, 2016 / Puration, Inc. (OTC PINK: PURA) today released a confirmation and update regarding its $1 million collaboration agreement with Spanish Peaks ScrumpDelicacies. Earlier this year, PURA and Spanish Peaks entered into a collaboration agreement to produce a line of cannabis Infused beverages. In conjunction with the agreement, Spanish Peaks conducted a cannabis beverage naming contest and announced the contest winners on October 21, 2016:

Puration and Spanish Peaks Announce Cannabis Beverage Name Contest Winners - First CannaCola Second CannaBliss and Third Canna Pur

Since the contest, Spanish Peaks has worked to establish brand name trademarks and to develop beverage formulations. Spanish Peaks reports that progress has been slower than anticipated due to the unfortunate and very unexpected passing of a senior Spanish Peaks partner and manager. Today, Spanish Peaks is happy to announce that the Company has made some exciting new progress anticipated to not only get the beverage production process back on track, but to add some exciting new features to the business plan. The new progress is expected to have a very positive impact on the existing collaboration agreement with PURA. Look for details on the new progress coming soon.

To learn more about Puration: purationinc.com
Follow Puration on Twitter: Puration710
Visit Puration on Facebook: Facebook.com/puration/

Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that Alkame will achieve significant sales, the failure to meet schedule or performance requirements of the Company's contracts, the Company's liquidity position, the Company's ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.

Puration Contact:

Brian Shibley, CEO

SOURCE: Puration